NAD+, NMN and NR
NAD+ precursor trials over weeks
The blood response is repeatable. The more interesting question is what changed during those weeks besides the blood.
What changed by 60 days?
Middle-aged adults received oral NMN in a 60-day randomized trial. Blood NAD+ increased, walking distance improved and quality-of-life scores improved compared with placebo. An estimate described as biological age did not increase. That estimate came from tests; the study did not demonstrate that human aging stopped.
Walking distance seems a firmer place to start than the phrase biological age. It connects the experiment to an ordinary ability, although a result at the end of a short trial still leaves persistence after treatment and future illness unresolved. The trial’s measured benefit deserves its precise size of claim.
Eight weeks of NR
NR is another precursor, an ingredient cells can use to make NAD+. In an 8-week trial in otherwise healthy overweight adults, the highest-amount group’s whole-blood NAD+ rose 142% above its starting level. Adverse events showed no significant difference from placebo.
That is a substantial laboratory change. I’m slower to assign a lasting health benefit to that blood result. Blood sampling tells us about the circulating pool; the state of NAD+ inside the brain, liver or muscle needs its own measurements.
Ten weeks and a muscle result
A 10-week NMN trial in prediabetic women after menopause found improved muscle insulin sensitivity: insulin helped their muscles take up glucose more readily. Body composition and HbA1c, a measure of longer-term blood-sugar control, stayed unchanged.
The combination is useful precisely because it resists a sweeping conclusion. A specific muscle response improved while other measurements did not. These were women with a particular metabolic condition, so applying the result to every healthy adult would add another assumption.
Why replacement appealed
NAD+ participates in the chemistry that releases energy from food, cycling between NAD+ and NADH. Other jobs, including DNA repair, consume it. The review of NAD+ metabolism during aging describes this balance of use and replacement and the enzymes drawing on the supply. NAD+ is a coenzyme; it has a different chemical structure from a peptide.
That biology gives the precursor experiments a sound question to ask. The 2025 review of human supplementation nevertheless found limited efficacy and sparse tissue-specific evidence. A compelling explanation of why replacement might help can coexist with modest clinical results.
Safety beyond an end date
The short trial observations cannot settle years of safety. Cancer cells also use NAD+, giving rise to a theoretical concern about supporting an existing cancer’s metabolism. The trials described here did not establish that NMN or NR causes cancer. That distinction matters whenever the concern is raised.
NMN, NR, swallowed NAD+ and intravenous NAD+ are different interventions. Controlled evidence for intravenous wellness claims is limited. NAD+ and these precursors have no FDA approval as drugs to treat aging; NMN’s supplement status has been disputed. Pharmacy-mixed NAD+ injections are unapproved products and carry contamination concerns. Changing the ingredient or route requires a fresh account of benefit and risk.